C - Chemistry – Metallurgy – 12 – Q
Patent
C - Chemistry, Metallurgy
12
Q
C12Q 1/68 (2006.01) A61K 48/00 (2006.01) A61P 35/00 (2006.01) C07K 7/04 (2006.01) C12N 15/09 (2006.01) C12Q 1/02 (2006.01) G01N 33/15 (2006.01) G01N 33/50 (2006.01) G01N 33/574 (2006.01)
Patent
CA 2735182
The present invention relates to the roles played by the TBC1D7 genes in cancer, in particular, lung cancer or esophageal cancer, or carcinogenesis and features a method for treating and/or preventing cancer, in particular, lung cancer or esophageal cancer by administering a double-stranded molecule against one or more of the TBC1D7 genes or a composition, vector or cell containing such a double stranded molecule. The present invention also features methods for diagnosing lung or assessing/determining the prognosis of a patient with lung, especially NSCLC or SCLC, or esophageal cancer, using one or more over-expressed genes selected from among TBC1D7. To that end, TBC1D7 may serve as a novel biomarker for lung cancer or esophageal cancer. Also, disclosed are methods of identifying compounds for treating and preventing lung or esophageal cancer, using as an index for their effect on the over-expression of one or more of TBC1D7 in the lung cancer or esophageal cancer.
La présente invention concerne les rôles joués par les gènes TBC1D7 dans le cancer, notamment le cancer du poumon ou le cancer de lsophage, ou la carcinogenèse, et concerne un procédé de traitement et/ou de prévention du cancer, notamment du cancer du poumon ou du cancer de lsophage par administration dune molécule bicaténaire contre un ou plusieurs des gènes TBC1D7 ou dune composition, dun vecteur ou dune cellule contenant une telle molécule bicaténaire. La présente invention concerne également des procédés de diagnostic ou dévaluation/détermination du pronostic dun patient atteint dun cancer du poumon, notamment NSCLC ou SCLC, ou dun cancer de lsophage, qui utilisent un ou plusieurs gènes surexprimés choisis parmi TBC1D7. A cette fin, TBC1D7 peut servir de nouveau biomarqueur pour le cancer du poumon ou le cancer de lsophage. Linvention concerne également des procédés didentification de composés pour traiter et prévenir le cancer du poumon ou de lsophage, qui utilisent en tant quindice leur effet sur la surexpression dun ou de plusieurs TBC1D7 dans le cancer du poumon ou le cancer de lsophage.
Daigo Yataro
Nakamura Yusuke
Togashi Akira
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Oncotherapy Science Inc.
LandOfFree
Tbc1d7 as tumor marker and therapeutic target for cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tbc1d7 as tumor marker and therapeutic target for cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tbc1d7 as tumor marker and therapeutic target for cancer will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1347308